Anavex Life Sciences (NASDAQ: AVXL) is likely to have an incredibly strong day in the market today, and for good reason. In a press release issued early this morning, the company announced that it has strengthened its management team, leading to excitement among investors and sending the stock screaming for the top. Today, we’ll talk about the news and what we’ll be watching for with regard to AVXL ahead.
AVXL Announces Additions To Management Team
As mentioned above, Anavex Life Sciences is likely to have an overwhelmingly strong day int he market today after announcing an addition to its management team. In a press release issued early this morning, the copany announced that it has brought Stephan Toutain, MS, MBA on as Senior Vice President of Operations and Claus van der Velden, PhD has joined the Board of Directors.
Stephan Toutain, MS, MBA, brings more than 25 years of drug development, general management, operations, commercial development, market access, and sales and marketing leadership to AVXL. He recently held the COO role at Interleukin Genetics and has worked with Alnylam Pharmaceuticals, Sarepta Therapeutics, Alexion Pharmaceuticals, and ore through his tenure in the industry.
Claus van der Velden, also brings significant experience to AVXL. Velden has incredible expertise in accounting and is currently the corporate head of Management Accounting, Internal Audit, and Risk Management at Stroeer SE & o KGaA, a $3 billion, publicly listed media company. In a statement, Christopher U. Missling, PhD, President and CEO at Anavex Life Sciences, had the following to offer:
We are delighted to welcome Stephan and Claus to Anavex. These appointments are a commitment to building our team in order to advance the development of ANAVEX2-73 in devastating neurological diseases like Rett syndrome, Alzheimer’s disease and Parkinson’s disease. Stephan is a seasoned business leader and an experienced operations and marketing executive who will lead the acceleration of our product development strategy, while Claus’ expertise will provide strategic guidance, compliance and accounting oversight on the Board of Directors.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on Anavex Life Sciences. In particular, we’re interested in following the ongoing development taking place surrounding the company’s impressive pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!